Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
The TARGET BP OFF-MED Trial
To obtain an assessment of the efficacy and safety of renal denervation by alcohol-mediated neurolysis using the Peregrine Kit in hypertensive subjects in the absence of antihypertensive medications.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Alcohol
- other: Sham control
Eligibility
Inclusion Criteria:
1. Has 3 office blood pressure measurements with a mean office systolic blood pressure
(SBP) of ≥140 mmHg and ≤180 mmHg, AND a mean office diastolic blood pressure (DBP) of
≥90 mmHg.
2. Subject is willing to discontinue any current antihypertensive medications during the
run-in period and the post-treatment period.
3. Has a mean 24-hour ambulatory SBP of ≥135 mmHg and ≤170 mmHg with ≥70% valid readings
Exclusion Criteria:
1. Subject has renal artery anatomy abnormalities.
2. Subject has an estimated glomerular filtration rate (eGFR) of ≤45 mL/min/1.73 m2,
based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation; or
is on chronic renal replacement therapy.
3. Subject has documented sleep apnea.
4. Subject has any of the following conditions: severe cardiac valve stenosis, heart
failure (New York Heart Association [NYHA] Class III or IV), chronic atrial
fibrillation, and known primary pulmonary hypertension (>60 mmHg pulmonary artery or
right ventricular systolic pressure).
5. Subject is pregnant or lactating at the time of enrollment or planning to become
pregnant during the trial time period (female subjects only).
6. Subject is being treated chronically (e.g. daily use) with NSAIDs, immunosuppressive
medications, or immunosuppressive doses of steroids. Aspirin therapy and nasal
pulmonary inhalants are allowed.
7. Subject has a history of myocardial infarction, unstable angina pectoris, or
stroke/TIA within 6 months prior to the planned procedure.
Ages Eligible for Study
18 Years - 80 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Psoriasis Clinical Trials
The TARGET BP OFF-MED Trial
To obtain an assessment of the efficacy and safety of renal denervation by alcohol-mediated neurolysis using the Peregrine Kit in hypertensive subjects in the absence of antihypertensive medications.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Alcohol
- other: Sham control
Eligibility
Inclusion Criteria:
1. Has 3 office blood pressure measurements with a mean office systolic blood pressure
(SBP) of ≥140 mmHg and ≤180 mmHg, AND a mean office diastolic blood pressure (DBP) of
≥90 mmHg.
2. Subject is willing to discontinue any current antihypertensive medications during the
run-in period and the post-treatment period.
3. Has a mean 24-hour ambulatory SBP of ≥135 mmHg and ≤170 mmHg with ≥70% valid readings
Exclusion Criteria:
1. Subject has renal artery anatomy abnormalities.
2. Subject has an estimated glomerular filtration rate (eGFR) of ≤45 mL/min/1.73 m2,
based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation; or
is on chronic renal replacement therapy.
3. Subject has documented sleep apnea.
4. Subject has any of the following conditions: severe cardiac valve stenosis, heart
failure (New York Heart Association [NYHA] Class III or IV), chronic atrial
fibrillation, and known primary pulmonary hypertension (>60 mmHg pulmonary artery or
right ventricular systolic pressure).
5. Subject is pregnant or lactating at the time of enrollment or planning to become
pregnant during the trial time period (female subjects only).
6. Subject is being treated chronically (e.g. daily use) with NSAIDs, immunosuppressive
medications, or immunosuppressive doses of steroids. Aspirin therapy and nasal
pulmonary inhalants are allowed.
7. Subject has a history of myocardial infarction, unstable angina pectoris, or
stroke/TIA within 6 months prior to the planned procedure.
Ages Eligible for Study
18 Years - 80 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Dermatology Clinical Trials
The TARGET BP OFF-MED Trial
To obtain an assessment of the efficacy and safety of renal denervation by alcohol-mediated neurolysis using the Peregrine Kit in hypertensive subjects in the absence of antihypertensive medications.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Alcohol
- other: Sham control
Eligibility
Inclusion Criteria:
1. Has 3 office blood pressure measurements with a mean office systolic blood pressure
(SBP) of ≥140 mmHg and ≤180 mmHg, AND a mean office diastolic blood pressure (DBP) of
≥90 mmHg.
2. Subject is willing to discontinue any current antihypertensive medications during the
run-in period and the post-treatment period.
3. Has a mean 24-hour ambulatory SBP of ≥135 mmHg and ≤170 mmHg with ≥70% valid readings
Exclusion Criteria:
1. Subject has renal artery anatomy abnormalities.
2. Subject has an estimated glomerular filtration rate (eGFR) of ≤45 mL/min/1.73 m2,
based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation; or
is on chronic renal replacement therapy.
3. Subject has documented sleep apnea.
4. Subject has any of the following conditions: severe cardiac valve stenosis, heart
failure (New York Heart Association [NYHA] Class III or IV), chronic atrial
fibrillation, and known primary pulmonary hypertension (>60 mmHg pulmonary artery or
right ventricular systolic pressure).
5. Subject is pregnant or lactating at the time of enrollment or planning to become
pregnant during the trial time period (female subjects only).
6. Subject is being treated chronically (e.g. daily use) with NSAIDs, immunosuppressive
medications, or immunosuppressive doses of steroids. Aspirin therapy and nasal
pulmonary inhalants are allowed.
7. Subject has a history of myocardial infarction, unstable angina pectoris, or
stroke/TIA within 6 months prior to the planned procedure.
Ages Eligible for Study
18 Years - 80 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Pediatric Dermatology Clinical Trials
The TARGET BP OFF-MED Trial
To obtain an assessment of the efficacy and safety of renal denervation by alcohol-mediated neurolysis using the Peregrine Kit in hypertensive subjects in the absence of antihypertensive medications.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Alcohol
- other: Sham control
Eligibility
Inclusion Criteria:
1. Has 3 office blood pressure measurements with a mean office systolic blood pressure
(SBP) of ≥140 mmHg and ≤180 mmHg, AND a mean office diastolic blood pressure (DBP) of
≥90 mmHg.
2. Subject is willing to discontinue any current antihypertensive medications during the
run-in period and the post-treatment period.
3. Has a mean 24-hour ambulatory SBP of ≥135 mmHg and ≤170 mmHg with ≥70% valid readings
Exclusion Criteria:
1. Subject has renal artery anatomy abnormalities.
2. Subject has an estimated glomerular filtration rate (eGFR) of ≤45 mL/min/1.73 m2,
based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation; or
is on chronic renal replacement therapy.
3. Subject has documented sleep apnea.
4. Subject has any of the following conditions: severe cardiac valve stenosis, heart
failure (New York Heart Association [NYHA] Class III or IV), chronic atrial
fibrillation, and known primary pulmonary hypertension (>60 mmHg pulmonary artery or
right ventricular systolic pressure).
5. Subject is pregnant or lactating at the time of enrollment or planning to become
pregnant during the trial time period (female subjects only).
6. Subject is being treated chronically (e.g. daily use) with NSAIDs, immunosuppressive
medications, or immunosuppressive doses of steroids. Aspirin therapy and nasal
pulmonary inhalants are allowed.
7. Subject has a history of myocardial infarction, unstable angina pectoris, or
stroke/TIA within 6 months prior to the planned procedure.
Ages Eligible for Study
18 Years - 80 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
The TARGET BP OFF-MED Trial
To obtain an assessment of the efficacy and safety of renal denervation by alcohol-mediated neurolysis using the Peregrine Kit in hypertensive subjects in the absence of antihypertensive medications.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Alcohol
- other: Sham control
Eligibility
Inclusion Criteria:
1. Has 3 office blood pressure measurements with a mean office systolic blood pressure
(SBP) of ≥140 mmHg and ≤180 mmHg, AND a mean office diastolic blood pressure (DBP) of
≥90 mmHg.
2. Subject is willing to discontinue any current antihypertensive medications during the
run-in period and the post-treatment period.
3. Has a mean 24-hour ambulatory SBP of ≥135 mmHg and ≤170 mmHg with ≥70% valid readings
Exclusion Criteria:
1. Subject has renal artery anatomy abnormalities.
2. Subject has an estimated glomerular filtration rate (eGFR) of ≤45 mL/min/1.73 m2,
based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation; or
is on chronic renal replacement therapy.
3. Subject has documented sleep apnea.
4. Subject has any of the following conditions: severe cardiac valve stenosis, heart
failure (New York Heart Association [NYHA] Class III or IV), chronic atrial
fibrillation, and known primary pulmonary hypertension (>60 mmHg pulmonary artery or
right ventricular systolic pressure).
5. Subject is pregnant or lactating at the time of enrollment or planning to become
pregnant during the trial time period (female subjects only).
6. Subject is being treated chronically (e.g. daily use) with NSAIDs, immunosuppressive
medications, or immunosuppressive doses of steroids. Aspirin therapy and nasal
pulmonary inhalants are allowed.
7. Subject has a history of myocardial infarction, unstable angina pectoris, or
stroke/TIA within 6 months prior to the planned procedure.
Ages Eligible for Study
18 Years - 80 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
The TARGET BP OFF-MED Trial
To obtain an assessment of the efficacy and safety of renal denervation by alcohol-mediated neurolysis using the Peregrine Kit in hypertensive subjects in the absence of antihypertensive medications.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Alcohol
- other: Sham control
Eligibility
Inclusion Criteria:
1. Has 3 office blood pressure measurements with a mean office systolic blood pressure
(SBP) of ≥140 mmHg and ≤180 mmHg, AND a mean office diastolic blood pressure (DBP) of
≥90 mmHg.
2. Subject is willing to discontinue any current antihypertensive medications during the
run-in period and the post-treatment period.
3. Has a mean 24-hour ambulatory SBP of ≥135 mmHg and ≤170 mmHg with ≥70% valid readings
Exclusion Criteria:
1. Subject has renal artery anatomy abnormalities.
2. Subject has an estimated glomerular filtration rate (eGFR) of ≤45 mL/min/1.73 m2,
based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation; or
is on chronic renal replacement therapy.
3. Subject has documented sleep apnea.
4. Subject has any of the following conditions: severe cardiac valve stenosis, heart
failure (New York Heart Association [NYHA] Class III or IV), chronic atrial
fibrillation, and known primary pulmonary hypertension (>60 mmHg pulmonary artery or
right ventricular systolic pressure).
5. Subject is pregnant or lactating at the time of enrollment or planning to become
pregnant during the trial time period (female subjects only).
6. Subject is being treated chronically (e.g. daily use) with NSAIDs, immunosuppressive
medications, or immunosuppressive doses of steroids. Aspirin therapy and nasal
pulmonary inhalants are allowed.
7. Subject has a history of myocardial infarction, unstable angina pectoris, or
stroke/TIA within 6 months prior to the planned procedure.
Ages Eligible for Study
18 Years - 80 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting